VTRS

시간 외 거래: 11.30

비아트리스 (VTRS)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측 주식 분할 배당 이력

Relative Volume:

비아트리스 Stock (VTRS) Company Profile

Healthcare (1174)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

최신 SEC 제출 서류

VTRS's Discussions on Twitter

VTRS을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
VTRS Viatris Inc	11.30	13.49B	15.05B	-883.30M	1.89B	-0.74
ZTS Zoetis Inc	165.89	74.84B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.24	41.78B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	12.92	40.96B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	21.92	24.83B	16.77B	-959.00M	1.37B	-0.85
NBIX Neurocrine Biosciences Inc	143.26	14.50B	2.24B	385.90M	440.10M	3.73

비아트리스 Stock (VTRS) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2024-07-19	재개	Jefferies	Buy
2023-10-23	다운그레이드	BofA Securities	Neutral → Underperform
2023-06-23	다운그레이드	Barclays	Equal Weight → Underweight
2023-04-24	다운그레이드	Barclays	Overweight → Equal Weight
2023-02-17	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2023-01-27	업그레이드	Jefferies	Hold → Buy
2022-11-10	업그레이드	UBS	Sell → Neutral
2022-11-08	업그레이드	Piper Sandler	Underweight → Neutral
2022-10-21	재개	Jefferies	Hold
2022-06-14	개시	UBS	Sell
2022-05-10	다운그레이드	Piper Sandler	Neutral → Underweight
2022-03-01	다운그레이드	BofA Securities	Buy → Neutral
2022-03-01	다운그레이드	Raymond James	Outperform → Mkt Perform
2021-06-15	개시	Citigroup	Neutral
2021-04-07	재개	RBC Capital Mkts	Outperform
2021-03-08	다운그레이드	Goldman	Buy → Neutral
2021-03-02	다운그레이드	JP Morgan	Overweight → Neutral
2021-02-26	다운그레이드	Wolfe Research	Outperform → Peer Perform
2021-01-05	개시	Argus	Hold
2020-12-14	개시	Bernstein	Mkt Perform

비아트리스 주식(VTRS)의 최신 뉴스

비아트리스 (VTRS) 재무 분석

비아트리스 (VTRS)

비아트리스 Stock (VTRS) Company Profile

VTRS을(를) 다른 주식과 비교

비아트리스 Stock (VTRS) Upgrades & Downgrades

비아트리스 주식(VTRS)의 최신 뉴스

EU Antitrust Chief Ribera: Consumer Protections Remain Top Priority - PYMNTS.com

Viatris Launch Plans Continue To Drag On, But Confidence High On Quartet - News & Insights

Is Viatris Inc. (VTRS) Among Wednesday’s Losers? - MSN

Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch

Viatris Inc (VTRS) Stock Price Down 4.56% on Jan 15 - GuruFocus.com

Is Viatris (VTRS) a Great Value Stock Right Now? - Yahoo Finance

Viatris firm in Cork paid $4bn of dividends as sales fell ahead of announced plant closure - Business Post

Systemic Lupus Erythematosus Pipeline Report 2024: Clinical Trials Progress and Therapeutic Advancements | Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, Roche - Barchart

Systemic Lupus Erythematosus Pipeline Report 2024: Clinical - openPR

Viatris Inc. stock rises Monday, outperforms market - MarketWatch

Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.

Is Viatris (VTRS) the Best Medical Stock to Buy Under $20? - Insider Monkey

Viatris Enters Oversold Territory - Nasdaq

Viatris Stock: Is VTRS Outperforming the Healthcare Sector? - MSN

Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc - The Globe and Mail

Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA - openPR

Another Disappointing Drug Import Alert from India - The People's Pharmacy

When (VTRS) Moves Investors should Listen - Stock Traders Daily

US FDA Blocks 11 Viatris Products, Except Four With Shortage Concerns - News & Insights

Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Con - GuruFocus.com

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times

Maternal Mental Health Market Is Booming Worldwide 2025-2032 | - openPR

Viatris Inc. stock falls Monday, underperforms market - MarketWatch

Viatris (VTRS) Shares Cross 4% Yield Mark - Nasdaq

Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes (NASDAQ:VTRS) - Seeking Alpha

FDA Blocks Viatris US Products With India Facility Import Alert - News & Insights

Viatris Inc. stock falls Friday, underperforms market - MarketWatch

Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter - FiercePharma

Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus.com

Viatris Inc. stock falls Monday, still outperforms market - MarketWatch

Maternal Mental Health Market Set to Witness Significant Growth by 2024-2031: Canopie, Pfizer Inc, Viatris - EIN News

Viatris Inc. stock falls Friday, still outperforms market - MarketWatch

Viatris Stock: Is VTRS Outperforming The Healthcare Sector? - Barchart

Viatris receives FDA warning letter for 11 drugs made at India plant - MSN

Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch

Viatris faces FDA import restrictions at Indian facility - The Pharma Letter

Viatris confirms receipt of warning letter, import alert for India facility - TipRanks

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference - Kilgore News Herald

US FDA restricts imports of some Viatris drugs made at India facility - Reuters

FDA restricts import of certain Viatris products due to plant violations - Investing.com UK

Viatris says India plant hit with FDA warning letter, import ban on 11 products - FiercePharma

Viatris Inc. stock falls Thursday, underperforms market - MarketWatch

What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn? - Insider Monkey

Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology - The Malaysian Reserve

Cenerimod shows promise in SLE trial, Viatris reports - Investing.com

Viatris announces publication of CARE study results - TipRanks

비아트리스 (VTRS) 재무 분석

매출

순이익

현금흐름

주당 순 이익

VTRS과 유사한 종목